In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on BioNano Genomics (BNGO - Research Report), with a price target of $6.00. The company's shares closed yesterday at $2.55.McCarthy covers the Healthcare sector, focusing on stocks such as Biocept, Plus Therapeutics, and SELLAS Life Sciences Group. According to TipRanks, McCarthy has an average return of -38.8% and a 14.16% success rate on recommended stocks. Currently, the analyst consensus on BioNano Genomics is a Moderate Buy with an average price target of $9.00.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $6.28 and a one-year low of $1.16.
https://www.tipranks.com/news/blurbs/maxim-group-reaffirms-their-buy-rating-on-bionano-genomics-bngo?utm_source=advfn.com&utm_medium=referral
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more Bionano Genomics Charts.
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more Bionano Genomics Charts.